[1]朱鸣峰.舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁的观察[J].医学信息,2019,(17):157-158.[doi:10.3969/j.issn.1006-1959.2019.17.053]
 ZHU Ming-feng.Observation on the Treatment of Post-stroke Depression with Shugan Jieyu Capsule Combined with Citalopram[J].Medical Information,2019,(17):157-158.[doi:10.3969/j.issn.1006-1959.2019.17.053]
点击复制

舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁的观察()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年17期
页码:
157-158
栏目:
中医中药
出版日期:
2019-09-01

文章信息/Info

Title:
Observation on the Treatment of Post-stroke Depression with Shugan Jieyu Capsule Combined with Citalopram
文章编号:
1006-1959(2019)17-0157-02
作者:
朱鸣峰
天津市静海区医院神经内4科,天津 301600
Author(s):
ZHU Ming-feng
Department of Neurology,Subject Four,Jinghai District Hospital,Tianjin 301600,China
关键词:
舒肝解郁胶囊西酞普兰脑卒中抑郁
Keywords:
Key words:Shugan Jieyu CapsuleCitalopramStrokeDepression
分类号:
R749.1
DOI:
10.3969/j.issn.1006-1959.2019.17.053
文献标志码:
A
摘要:
目的 观察舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁的临床效果。方法 选取2017年6月~2018年12月在我院诊治的88例脑卒中后抑郁患者,随机分为对照组和观察组,各44例。对照组采用舒肝解郁胶囊治疗,观察组在对照组治疗的基础上加用西酞普兰治疗,比较两组治疗后HAMD评分、神经功能缺损评分、生活能力改善以及不良反应发生情况。结果 观察组治疗后HAMD评分为(10.13±2.18)分、神经功能缺损评分为(9.72±3.21)分,均低于对照组的(16.72±2.42)分、(13.02±3.13)分,差异有统计学意义(P<0.05);观察组患者生活能力改善率(72.72%)优于对照组(45.45%),差异有统计学意义(P<0.05);两组治疗期间均未发生明显不良反应。结论 舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁效果确切,有助于提高患者生活能力,改善神经功能缺损,其临床治疗效果优于单纯采用舒肝解郁胶囊治疗效果,且较安全。
Abstract:
Abstract:Objective To observe the clinical effect of Shugan Jieyu Capsule combined with citalopram in the treatment of post-stroke depression. Methods 88 patients with post-stroke depression who were treated in our hospital from June 2017 to December 2018 were randomly divided into control group and observation group, 44 cases each. The control group was treated with Shugan Jieyu Capsule. The observation group was treated with citalopram on the basis of the control group. The HAMD score, neurological deficit score, improvement of living ability and adverse reactions were compared between the two groups.Results The HAMD score of the observation group was (10.13±2.18) and the neurological deficit score was (9.72±3.21), which was lower than that of the control group (16.72±2.42) and (13.02±3.13),the difference was statistically significant(P<0.05); the improvement rate of life ability of the observation group (72.72%) was better than that of the control group (45.45%), the difference was statistically significant (P<0.05); no significant adverse reactions occurred during the treatment period.Conclusion Shugan Jieyu Capsule combined with citalopram is effective in treating post-stroke depression, which can improve the patient's ability to live and improve neurological deficit. The clinical treatment effect is better than that of Shugan Jieyu Capsule, and it is safer.

参考文献/References:

[1]顾玉宝,刘敬霞,王枫,等.人参皂苷治疗缺血性脑卒中研究进展[J].新中医,2017(4):194-197. [2]林峰,陈明.舒肝解郁胶囊合并奥氮平治疗女性精神分裂症阴性症状伴轻中度抑郁状态30例临床分析[J].中国卫生标准管理,2018,9(3):102-104. [3]王进良,刘晓伟,杨国平,等.西酞普兰治疗抑郁症的临床观察[J].临床精神医学杂志,2014,14(1):16-17. [4] 文军,李永涛,李淼, 等.小剂量米氮平联合疏肝解郁胶囊治疗脑卒中后抑郁症的疗效观察[J].临床合理用药杂志,2015,(10):66-67. [5]聂伟,张永祥,周金黄.金丝桃提取物抗抑郁作用研究与展望[J].中国实验方剂学杂志,2011,7(1):59-61.

更新日期/Last Update: 2019-09-01